Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation
Madiha Iqbal(Mayo Clinic in Florida), Mohamed A. Kharfan‐Dabaja(Jacksonville College), Jonathon B. Cohen(Emory University), Silvia Montoto(Queen Mary University of London), Mehdi Hamadani(Medical College of Wisconsin), Craig S. Sauter(Memorial Sloan Kettering Cancer Center), Caron A. Jacobson(Dana-Farber Cancer Institute), Olalekan O. Oluwole(Vanderbilt University), Martin Dreyling(LMU Klinikum), Mazyar Shadman(University of Washington), Julio Chavez(Moffitt Cancer Center), Ranjana H. Advani(Stanford Medicine), Carla Casulo(University of Rochester Medical Center), Abraham S. Kanate(HonorHealth), Veronika Bachanová(University of Minnesota), Brad S. Kahl(UW Health University Hospital), Nada Hamad(UNSW Sydney), Richard T. Maziarz(Oregon Health & Science University), Lihua E. Budde(City Of Hope National Medical Center), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), John Kuruvilla(Princess Margaret Cancer Centre), Gilles Salles(Memorial Sloan Kettering Cancer Center), Ambuj Kumar(University of South Florida), Peter Dreger(Heidelberg University), Anna M. Sureda(Institut Català d'Oncologia), Manali Kamdar(University of Colorado Cancer Center), Bertram Glaß(Helios Hospital Berlin-Buch), Sonali M. Smith(University of Chicago)
Cited by 12
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k